We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Dried Blood Assessment Equivalent to Drawn Blood Samples

By LabMedica International staff writers
Posted on 14 Aug 2017
A self-sampling method for therapeutic drug monitoring (TDM) of biologicals was developed that should enhance TDM implementation by patients with various autoimmune conditions.

Investigators at the Sanquin Blood Supply Foundation (Amsterdam, the Netherlands) used the rheumatoid arthritis treatment drug adalimumab to establish the feasibility of replacing drawn blood samples with dried blood spots obtained by finger prick.

Adalimumab is a TNF-inhibiting, anti-inflammatory medication. More...
It binds to tumor necrosis factor-alpha (TNFalpha), which normally binds to TNFalpha receptors, leading to the inflammatory response of autoimmune diseases. By binding to TNFalpha, adalimumab reduces this inflammatory response. Because TNFalpha is also part of the immune system, which protects the body from infection, treatment with adalimumab may increase the risk of infections. For this reason the U.S. Food and Drug Administration issued a black box warning to doctors, which appears in the product labeling of adalimumab and other TNF-inhibiting drugs, instructing them to screen and monitor potential patients more carefully.

The investigators compared adalimumab and anti-adalimumab antibody (ADA) concentration measurements in dried blood spots (DBS) obtained from finger pricks with measurements in serum obtained via venipuncture, from 161 patients with rheumatic inflammatory diseases. Adalimumab and ADA concentration were assessed by ELISA and antigen binding test (ABT), respectively.

Results revealed that adalimumab and ADA concentrations obtained by the finger prick/DBS method correlated well with serum results from the same patient (correlation coefficient greater than 0.87). Interestingly, antibody concentrations (adalimumab, ADA, or total immunoglobulin G) in DBS from finger prick, but not albumin, were systematically lower compared to serum. Experiments on spiked blood samples demonstrated a quantitative recovery for all tested proteins in DBS, suggesting a slightly different protein composition of blood collected via finger prick versus venipuncture. Therefore, the investigators established a correction factor of approximately 1.2 to relate finger prick/DBS values to serum values.

"Easy home sampling at different time points will benefit patients and could help to prescribe biologics optimally," said senior author Dr. Karien Bloem, post-doctoral researcher in immunopathology at Sanquin Blood Supply Foundation.

The study was published in the August 9, 2017, online edition of the British Journal of Clinical Pharmacology.

Related Links:
Sanquin Blood Supply Foundation


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.